Navigation Links
Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Date:9/1/2011

tment for infectious diarrhea. Additional information can be found at http://www.optimerpharma.com.

Contacts
Optimer Pharmaceuticals, Inc.
David Walsey, Vice President, Investor Relations and Corporate Communications
858-909-0736

Canale Communications, Inc.
Jason I. Spark, Senior Vice President
619-849-6005


'/>"/>
SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Clinical Infectious Diseases Publishes Subgroup Analysis Showing Optimers DIFICID™ (fidaxomicin) Tablets Exhibited Higher Clinical Cure and Global Cure Rates Than Vancomycin in Patients with Clostridium difficile-Associated Diarrhea (CDAD) Receivin
2. Optimer Pharmaceuticals Reports Second Quarter 2011 Financial Results
3. Optimer Launches DIFICID™ (fidaxomicin) Tablets for Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) in Patients 18 Years of Age and Older
4. Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
5. Optimer Pharmaceuticals to Present at the Jefferies 2011 Global Healthcare Conference
6. Optimer Pharmaceuticals Reports First Quarter 2011 Financial Results
7. Optimer Pharmaceuticals Expands Senior Management Team
8. Optimer Pharmaceuticals to Present at May 2011 Investor Conferences
9. Optimer Pharmaceuticals and Cubist Pharmaceuticals Announce Collaboration to Co-Promote DIFICID™ (Fidaxomicin) for Clostridium difficile Infection in the United States
10. Optimer Announces that the U.S. Food and Drug Administrations Anti-Infective Drugs Advisory Committee Voted Unanimously to Recommend Approval of Novel Antibiotic Dificid™ for Treatment of Patients with Clostridium difficile infection (CDI)
11. Trading Halted Today in Optimer Pharmaceuticals Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)...  Seres Health, a clinical-stage therapeutics company developing ... microbiome, announced today that Dr. David Cook ... Chief Scientific Officer, will be presenting at the ... (ICAAC). The presentation will highlight the scientific and ... bacterial spores derived from the human microbiome, and ...
(Date:8/28/2014)... PITTSBURGH , Aug. 28, 2014 /PRNewswire-iReach/ -- ... exhibiting at the 9 th Annual Global ... , September 8-9 th . The Global ... industry leaders in small molecule and biologic pharmaceutical ... address challenges that today,s manufacturers face, such as ...
(Date:8/28/2014)... Aug. 28, 2014 Reportlinker.com ... report is available in its catalogue: ... Asia-Pacific Markets to 2020 - Novel ... in Newly Diagnosed and Recurrent GBM ... Glioblastoma Multiforme Therapeutics ...
Breaking Medicine Technology:Seres Health to Present Clinical Findings at ICAAC 2014 Conference 2Gateway Analytical to Promote Particulate Identification Services at the 9th Annual Global Pharma Manufacturing Summit 2Gateway Analytical to Promote Particulate Identification Services at the 9th Annual Global Pharma Manufacturing Summit 3Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 2Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 3Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 4Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 5Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 6Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 7Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 8Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 9
... WILMINGTON, Del., Oct. 26 Next Intelligence Corporation ( ... today announced the expansion of its channel program for ... and system integrators (SI) to explore the growing health ... members sales leads, education on technical and selling aspects ...
... (Nasdaq: GTIV ), the nation,s largest provider of ... present at the Oppenheimer 21st Annual Healthcare Conference in New ... and the Credit Suisse 2010 Healthcare Conference in Phoenix, AZ ... 10, 2010. The presentations will be available to ...
Cached Medicine Technology:Next Intelligence Health Expands US Channel Program 2Gentiva® Health Services to Present at the Oppenheimer and Credit Suisse Healthcare Conferences 2Gentiva® Health Services to Present at the Oppenheimer and Credit Suisse Healthcare Conferences 3
(Date:8/29/2014)... Aug. 29, 2014 (HealthDay News) -- The main ... the Middle East and North Africa originated in ... studied so-called community-acquired methicillin-resistant Staphylococcus aureus ... have not recently been hospitalized. These infections typically ... person-to-person contact or through touching contaminated objects such ...
(Date:8/29/2014)... August 29, 2014 For the fifth ... (Meso Foundation) will be observing September 26th as Mesothelioma ... Plaza, in New York. , Members of the ... RSVP . The Foundation will be providing t-shirts and ... years, mesothelioma community members have received attention from ...
(Date:8/29/2014)... 29, 2014 PreDiabetes Centers , the ... season by offering Web shoppers a 20% discount off orders ... the Company’s online healthy living shop, beginning September 1. ... priority when heading into the chilly fall season. , Autumn’s ... this season, people usually ditch the healthy salads and opt ...
(Date:8/29/2014)... August 29, 2014 Innovations Television, produced by ... upcoming episodes of Innovations, focusing on health and elderly care, ... show the number of Americans over 65 will nearly double ... to 20% in 2030, for a total of 72 million ... health, most have at least one chronic condition and use ...
(Date:8/29/2014)... Raleigh, NC (PRWEB) August 29, 2014 ... validated the idea that progression-free survival correlates with overall ... article on the new research. Click here to ... UK and The Netherlands studied the cases of 523 ... European chemotherapy studies. , “PFSR-18 [progression-free survival at ...
Breaking Medicine News(10 mins):Health News: European MRSA Originated in Sub-Saharan Africa, Study Finds 2Health News:Organization to Raise Awareness of Mesothelioma on the Today Show 2Health News:PreDiabetes Centers Online Store Launches Fall Savings Event 2Health News:Innovations with Ed Begley, Jr., Seeking Content for Upcoming Series on Health and Elder Care 2Health News:European Study Says Disease Progression Predicts Mesothelioma Survival Better Than Treatment Response, According to Surviving Mesothelioma 2
... Heart Failure Nurses in Boston, June ... 26-28, ... (AAHFN) 2008 Annual Meeting "Raising the Bar in Heart,Failure Care" is scheduled ... research and ways to,improve patient care. The compelling agenda and wonderful ...
... VYTEX(TM) NRL: THE NEW STANDARDIZED SOURCE MATERIAL FOR THE ... PRODUCTS ... Rapra Technology Limited has invited,Vystar Corporation to present its ... Dispersions Conference 2008 in Madrid in,January. "Vytex(TM) Natural ...
... patients with advanced kidney cancer whose options run out after ... , The study, presented today (Wednesday) at the European ... drug, axitinib, shrank tumours and delayed progression of the disease ... to treat. , In the study, scientists gave axitinib to ...
... Paramount Acquisition,Corp. (OTC Bulletin Board: PMQC, PMQCU, PMQCW) ... directors has established the close of,business on October 1, ... will be entitled to receive notice of and to ... held to consider and vote,on the previously announced acquisition ...
... Consider Proposals and Variations, LOS ANGELES, ... ISCR) a leading e-health Wi-Fi PDA technology ... DME and EMR applications,and the distributor of ... surgical products, announced today that its Board ...
... Spain: Using an ultrasound-guided fine needle to biopsy lymph ... worldwide from having to undergo unnecessary and sometimes unpleasant ... research indicates. , In a study presented today ... Barcelona, scientists found that the less invasive technique produced ...
Cached Medicine News:Health News:AAHFN's 2008 Annual Meeting in Boston Will Be 'Raising the Bar in Heart Failure Care' 2Health News:Global Latex Conference to Showcase Vytex(TM) NRL 2Health News:Experimental drug shows promise in advanced kidney cancer 2Health News:Paramount Acquisition Corp. Announces Record Date of October 1, 2007 for Proposed Acquisition of Chem Rx 2Health News:Paramount Acquisition Corp. Announces Record Date of October 1, 2007 for Proposed Acquisition of Chem Rx 3Health News:Paramount Acquisition Corp. Announces Record Date of October 1, 2007 for Proposed Acquisition of Chem Rx 4Health News:InstaCare Corp. Reviewing M&A Plans 2Health News:Less invasive lymph node biopsy method could spare thousands unnecessary operations 2
Cuffed pediatric endotracheal tubes, available from 2.5 mm to 4.5 mm inside diameter. Ruschelit® PVC. Magill tip - nasoral. X-ray opaque line. Graduated. Single use. Sterile...
Ruschelit® PVC. Murphy eye-nasoral. Black positioning ring. High volume/low pressure cuff. X-ray opaque line. Graduated. Single use....
Ruschelit® PVC. Siliconized. Stainless steel spiral reinforced. Murphy eye. High volume/low pressure cuff. Connector is permanently fixed into the tube. X-ray opaque. Graduated. Single use. Steri...
... eye. Laser resistant foam surrounds the lower 17cm ... other) 40cm (16") long, Single Use. The tracheal ... optimum visibility within the operating site, while maintaining ... laser-guard of approx. 17cm in length proximal to ...
Medicine Products: